This article is for informational purposes only. Cannabis can interact with many medications. Always consult your healthcare provider before combining cannabinoid products with any medication.
By CaliforniaCannabinoids Safety Desk | Last verified: July 2026
Overview: Cannabis Use in Pregnancy and Lactation
Cannabis use during pregnancy and breastfeeding represents one of the most significant safety concerns in reproductive medicine today. Unlike many other substances where research is limited, the evidence base for cannabis exposure during these critical windows is growing substantially, and current data from observational studies and animal models indicate measurable risks to fetal and infant development.
According to the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP), cannabinoids—particularly THC—cross the placental barrier readily and accumulate in breast milk at concentrations higher than maternal serum levels. This creates a unique pharmacokinetic challenge: the developing fetus and nursing infant may experience cannabinoid exposure levels disproportionate to maternal dosing.
In California, where cannabis is legal for adult use, dispensary data suggests that approximately 9-12% of pregnant individuals continue cannabis use, often for symptom management of nausea, anxiety, or chronic pain. However, medical evidence does not support cannabis as a first-line treatment for any pregnancy-related condition, and safer alternatives exist across all therapeutic indications.
Mechanism of Risk: How Cannabinoids Affect Fetal and Infant Development
THC’s mechanism of action involves binding to cannabinoid receptors (CB1 and CB2) throughout the central nervous system. The developing brain expresses high densities of CB1 receptors during the second and third trimester, making this period a critical window of vulnerability.
During fetal development, cannabinoid receptor activation disrupts normal neurogenesis, synaptogenesis, and neural migration. THC exposure during this period has been associated with:
- Altered gray matter development — affecting prefrontal cortex, anterior cingulate, and striatal regions
- Disrupted dopaminergic and serotonergic signaling — foundational neurotransmitter systems
- Impaired synaptic pruning — the normal developmental process of neural refinement
- Reduced placental blood flow — secondary to cannabinoid-mediated vasodilation
In breastfeeding, THC’s lipophilic nature causes it to accumulate in breast tissue. Studies have detected THC in breast milk at concentrations 5-8 times higher than maternal plasma levels. For a nursing infant with immature hepatic metabolism, this represents significant systemic exposure. CBDhref=”https://californiacannabinoids.com/cbd-cannabidiol-ingredient/”>CBD, while generally considered safer, also appears in breast milk and may inhibit infant hepatic metabolism of other compounds.
Drug Interactions: Medication Combinations with Cannabis
Cannabis use during pregnancy must be considered alongside other medications the pregnant individual may be taking. Several critical drug interactions have been documented:
CYP3A4 and CYP2C9 Metabolism: Both THC and CBD inhibit hepatic cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. This is especially problematic during pregnancy when metabolic clearance of certain medications is already altered. Increased drug levels can result in maternal toxicity and altered fetal exposure.
CNS Depressants: Combining cannabis with sedating medications—including SSRIs, anticonvulsants, antipsychotics, and opioids—amplifies central nervous system depression. While pregnant individuals typically avoid opioids, SSRIs are commonly prescribed for depression and anxiety during pregnancy. The interaction is additive and may increase fall risk and impair cognitive function.
Anticoagulants: Warfarin metabolism is inhibited by cannabinoids. Pregnant individuals requiring anticoagulation (thrombophilia, mechanical heart valves) face increased bleeding risk if cannabis is added.
Specific Medication Interactions Table
| Drug/Drug Class | Interaction Mechanism | Severity | Recommended Action |
|---|---|---|---|
| Sertraline, Paroxetine (SSRIs) | Additive CNS depression; potential serotonin syndrome with high-dose THC | Moderate | Avoid combination; use alternative anxiety management |
| Warfarin (Coumadin) | CYP2C9 inhibition; increased warfarin levels | High | Contraindicated; monitor INR closely if unavoidable |
| Phenytoin, Levetiracetam (Anticonvulsants) | CYP3A4 inhibition; altered seizure threshold control | High | Avoid; seizure breakthrough risk unacceptable in pregnancy |
| Methadone | CYP3A4 inhibition; CNS additive effects | High | Avoid; risk of opioid toxicity and neonatal withdrawal |
| Labetalol, Nifedipine (Antihypertensives) | Additive hypotensive effects; cannabinoid-mediated vasodilation | Moderate | Monitor BP; adjust dosing with provider oversight |
| Tacrolimus, Cyclosporine (Immunosuppressants) | CYP3A4 inhibition; altered drug levels in transplant patients | High | Contraindicated; therapeutic drug monitoring essential if unavoidable |
| Fluconazole, Ketoconazole (Antifungals) | Both are CYP3A4 inhibitors; synergistic enzyme inhibition | Moderate to High | Avoid concurrent use; space dosing if essential |
At-Risk Populations: Contraindications in Pregnancy and Lactation
All Pregnant Individuals: Cannabis is contraindicated throughout pregnancy. Current evidence links prenatal exposure to reduced birth weight (mean reduction 140-190 grams in exposed pregnancies), preterm birth, small for gestational age classification, and potential neurobehavioral effects including lower Apgar scores and altered neonatal reflexes.
Breastfeeding Individuals: THC excretion into breast milk is significant and prolonged. Infants cannot metabolize cannabinoids efficiently, leading to bioaccumulation. Case reports document infant lethargy, poor feeding, and developmental delays associated with maternal cannabis use during lactation.
Individuals with History of Cannabis Hyperemesis Syndrome (CHS): Pregnant individuals with CHS face compounded nausea and hyperemesis gravidarum, making symptom management more difficult and increasing dehydration risk and electrolyte imbalance.
Those with Mental Health Conditions: While some pregnant individuals use cannabis for anxiety or depression, cannabinoid use may paradoxically worsen mood symptoms in certain individuals and carries theoretical risk of psychosis exacerbation. SSRIs and other evidence-based psychiatric medications are safer first-line options.
Individuals with Placental Insufficiency or Intrauterine Growth Restriction: Cannabis-induced reduction in placental blood flow is particularly dangerous in pregnancies already at risk for fetal growth compromise.
Clinical Evidence: What Research Demonstrates
Major cohort studies from Canada and the United States (including data from Kaiser Permanente and the Nurses’ Health Study II) have documented outcomes in cannabis-exposed pregnancies:
- Meta-analyses show consistent association between prenatal cannabis use and reduced birth weight (pooled odds ratio 1.34 for small for gestational age)
- Longitudinal neurodevelopmental follow-up studies detect subtle deficits in executive function, attention regulation, and impulse control at school age in children prenatally exposed to cannabis
- Neuroimaging studies show structural differences in prefrontal and limbic regions in adolescents with prenatal cannabis exposure
The mechanism is dose and timing-dependent, with second and third trimester exposure showing stronger associations with birth outcomes than first trimester exposure alone.
Safe Use Guidelines: Harm Reduction in Pregnancy and Lactation
Primary Recommendation: Complete Abstinence
The safest approach for pregnant and breastfeeding individuals is complete discontinuation of cannabis. No safe threshold has been established, and the potential benefits do not outweigh documented risks.
If Discontinuation is Challenging:
- Seek medication-assisted support: Work with a reproductive psychiatrist or maternal-fetal medicine specialist to transition to evidence-based alternatives for anxiety, nausea, or pain
- Identify symptom drivers: Pregnancy nausea often responds to ginger, vitamin B6, acupuncture, or pharmaceutical options (ondansetron, metoclopramide)
- Address substance use disorder: If cannabis dependence is present, medication-assisted treatment programs specifically trained in perinatal care are available across California
For Breastfeeding Individuals: If cannabis use occurs postpartum, pumping and discarding expressed milk for 48-72 hours after use may reduce infant exposure, though this should be done under healthcare provider guidance.
When to Seek Immediate Medical Help
Pregnant individuals using cannabis should seek urgent care if experiencing:
- Severe hyperemesis: Inability to keep fluids or food down despite cannabis use suggests need for hospitalization and medication management
- Preterm labor symptoms: Vaginal bleeding, fluid leakage, regular contractions—cannabis use may mask these warning signs
- Acute psychiatric symptoms: Hallucinations, delusions, severe anxiety, or suicidal ideation
- Signs of cannabinoid hyperemesis: Cyclic severe vomiting unresponsive to standard antiemetics
Breastfeeding individuals should contact their pediatrician if the infant exhibits:
- Unusual lethargy or difficulty waking for feeds
- Poor weight gain or failure to regain birth weight
- Developmental delays in motor or social milestones
- Tremors or irritability
California Legal and Regulatory Context
California’s Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) does not restrict cannabis sales based on pregnancy status. However, California regulations require dispensaries to post warning signs about cannabis and pregnancy. The state has not established pregnancy-specific cannabinoid product restrictions, though some local jurisdictions have implemented stricter labeling requirements.
Healthcare providers in California are not mandated to report cannabis use during pregnancy to child protective services unless there is evidence of child abuse or neglect. This allows for confidential counseling and support without legal consequences.
For more information on cannabinoid safety across different populations, see our comprehensive drug interactions guide and our resource on cannabinoid use in special populations.
Conclusion and Provider Recommendations
Cannabis use during pregnancy and breastfeeding poses documented risks to fetal development and infant health that are not offset by therapeutic benefits. Current evidence supports complete abstinence as the safest approach. Healthcare providers should counsel pregnant individuals on these risks, screen routinely for cannabis use, and offer evidence-based alternatives for common pregnancy complaints.
Pregnant individuals struggling with cannabis dependence should be connected with perinatal substance use disorder specialists and harm reduction programs that do not mandate abstinence but provide compassionate, medication-supported care throughout pregnancy and postpartum.